Urinary incontinence refers to the involuntary leakage of urine. Factors such as increased body mass index, diabetes, pregnancy, and childbirth are linked with a higher risk of developing urinary incontinence. Studies indicate that around 24% to 45% of women experience urinary incontinence, with 9% to 39% of older women (aged over 60) reporting this condition on a daily basis. Thus, the increasing incidence of urinary incontinence is fuelling the demand for innovative drug solutions. Moreover, the introduction of novel drug delivery systems is expected to improve the efficacy and compliance of urinary incontinence treatments in the coming years.
Major companies involved in the urinary incontinence pipeline drugs market include Versameb AG, Cook MyoSite, and EG 427, among others.
Leading drugs currently under the pipeline include AMDC-USR (iltamiocel) and VMB-100, among others.
Advancements in drug development such as extended-release formulations and combination therapies are anticipated to positively influence the drug pipeline landscape.
The Urinary Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into urinary incontinence drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for urinary incontinence. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from urinary incontinence.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to urinary incontinence.
Urinary incontinence is a loss of bladder control that causes the unintentional passing of urine. In the United Kingdom, it is estimated that 34% of women are affected by urinary incontinence and more than 2 million men experience the condition. Urinary incontinence is associated with an increased risk of hospital acquired urinary tract infections, pressure ulcers, and skin infections, among others.
There are several types of urinary incontinence: mixed, stress, functional, urge, and overflow incontinence. Treatments for urinary incontinence vary depending on the type, severity, and underlying cause. Anticholinergics such as oxybutynin and tolterodine are recommended for overactive bladder to relax the bladder muscles. Topical estrogen is often prescribed to postmenopausal women to improve bladder control. Further, there is a growing R&D investment in novel compounds, biologics, and personalized medicine that can effectively treat urinary incontinence.
This section of the report covers the analysis of urinary incontinence drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for urinary incontinence.
The drug molecule categories covered under the urinary incontinence pipeline analysis include small molecules, biologics, cell therapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for urinary incontinence.
The EMR report for the urinary incontinence drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in urinary incontinence clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Cook MyoSite, the objective of this double-blind randomized Phase III study is to compare the efficacy and safety of the autologous muscle derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) with placebo in around 96 female participants with persistent or recurrent stress urinary incontinence post-surgical treatment.
Versameb AG is conducting a Phase II clinical trial to evaluate the investigational drug VMB-100, an mRNA encoding for IGF-1, for the treatment of moderate stress urinary incontinence. The study has enrolled an estimated 30 female subjects and is expected to be completed by November 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Urinary Incontinence Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within urinary incontinence pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share